Related references
Note: Only part of the references are listed.Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak et al.
CLINICAL CANCER RESEARCH (2021)
Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
Aria Sabbagh et al.
CLINICAL CANCER RESEARCH (2021)
Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas.
Yazmin Odia et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Usefulness of assessment of circulating tumor DNA(ctDNA) of cerebrospinal fluid(CSF) samples for early detection of brain metastasis (BrM) in patients with triple-negative breast cancer (TNBC).
Lucrezia Raimondi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles.
Marta Domenech et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
Manmeet Singh Ahluwalia et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
Patrick Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.
Andrew E. Sloan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.
Priscilla Kaliopi Brastianos et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified gamma delta t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.
Louis B. Nabors et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A phase I/IIa study to evaluate the safety and efficacy of blood-brain barrier (BBB) opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin.
Ahmed Idbaih et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Cerebrospinal fluid circulating tumor cells as a predictive biomarker for proton craniospinal irradiation for leptomeningeal metastases.
N. Ari Wijetunga et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI).
Francois Ducray et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations
Daniel Y. Zhang et al.
CLINICAL CANCER RESEARCH (2020)
Proteasome inhibition for the treatment of glioblastoma
Patrick Roth et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Overcoming the Blood-Brain Barrier with an Implantable Ultrasound Device
Adam M. Sonabend et al.
CLINICAL CANCER RESEARCH (2019)
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations
Tareq A. Juratli et al.
CANCER (2019)
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
Andrew S. Chi et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Annick Desjardins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
Deborah T. Blumenthal et al.
NEURO-ONCOLOGY (2017)
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
Yanxin Lu et al.
CANCER RESEARCH (2017)
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy
Priscilla K. Brastianos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy
Priscilla K. Brastianos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Nucleo-cytoplasmic transport as a therapeutic target of cancer
Giovanni Luca Gravina et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
Priscilla K. Brastianos et al.
NATURE GENETICS (2014)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
